These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 33522380)

  • 41. The bivalent factor H binding protein meningococcal serogroup B vaccine elicits bactericidal antibodies against representative non-serogroup B meningococci.
    Harris SL; Tan C; Andrew L; Hao L; Liberator PA; Absalon J; Anderson AS; Jones TR
    Vaccine; 2018 Oct; 36(45):6867-6874. PubMed ID: 30269916
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Characterization of fHbp, nhba (gna2132), nadA, porA, and sequence type in group B meningococcal case isolates collected in England and Wales during January 2008 and potential coverage of an investigational group B meningococcal vaccine.
    Lucidarme J; Comanducci M; Findlow J; Gray SJ; Kaczmarski EB; Guiver M; Vallely PJ; Oster P; Pizza M; Bambini S; Muzzi A; Borrow R
    Clin Vaccine Immunol; 2010 Jun; 17(6):919-29. PubMed ID: 20375242
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Progressive decrease in the potential usefulness of meningococcal serogroup B vaccine (4CMenB, Bexsero®) in Gipuzkoa, Northern Spain.
    Pérez-Trallero E; Esnal O; Marimón JM
    PLoS One; 2014; 9(12):e116024. PubMed ID: 25541709
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Invasive serogroup B meningococci in England following three years of 4CMenB vaccination - First real-world data.
    Lucidarme J; Bai X; Lekshmi A; Clark SA; Willerton L; Ribeiro S; Campbell H; Serino L; De Paola R; Holland A; Louth J; Ramsay ME; Ladhani SN; Borrow R
    J Infect; 2022 Feb; 84(2):136-144. PubMed ID: 34838814
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A phase III observer-blind randomized, controlled study to evaluate the immune response and the correlation with nasopharyngeal carriage after immunization of university students with a quadrivalent meningococcal ACWY glycoconjugate or serogroup B meningococcal vaccine.
    Read RC; Dull P; Bai X; Nolan K; Findlow J; Bazaz R; Kleinschmidt A; McCarthy M; Wang H; Toneatto D; Borrow R
    Vaccine; 2017 Jan; 35(3):427-434. PubMed ID: 27912986
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB).
    Bettinger JA; Scheifele DW; Halperin SA; Vaudry W; Findlow J; Borrow R; Medini D; Tsang R;
    Vaccine; 2013 Dec; 32(1):124-30. PubMed ID: 23588089
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Reduced schedules of 4CMenB vaccine in infants and catch-up series in children: Immunogenicity and safety results from a randomised open-label phase 3b trial.
    Martinón-Torres F; Safadi MAP; Martinez AC; Marquez PI; Torres JCT; Weckx LY; Moreira ED; Mensi I; Calabresi M; Toneatto D
    Vaccine; 2017 Jun; 35(28):3548-3557. PubMed ID: 28533054
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Molecular typing of group B Neisseria meningitidis'subcapsular antigens directly on biological samples demonstrates epidemiological congruence between culture-positive and -negative cases: A surveillance study of invasive disease over a 13-year period.
    Lodi L; Moriondo M; Nieddu F; Ricci S; Guiducci S; Lippi F; Canessa C; Calistri E; Citera F; Giovannini M; Indolfi G; Resti M; Azzari C
    J Infect; 2021 Apr; 82(4):28-36. PubMed ID: 33610687
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Genetic distribution of noncapsular meningococcal group B vaccine antigens in Neisseria lactamica.
    Lucidarme J; Gilchrist S; Newbold LS; Gray SJ; Kaczmarski EB; Richardson L; Bennett JS; Maiden MC; Findlow J; Borrow R
    Clin Vaccine Immunol; 2013 Sep; 20(9):1360-9. PubMed ID: 23803905
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Sequencing analysis of the antigens included in the four-component  vaccine against serogroup B meningococcus in Czech isolates of Neisseria meningitidis from 2007-2013].
    Křížová P; Musílek M; Vacková Z; Bečvářová Z; Kozáková J
    Epidemiol Mikrobiol Imunol; 2014 Feb; 63(1):61-8. PubMed ID: 24730996
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study.
    Santolaya ME; O'Ryan ML; Valenzuela MT; Prado V; Vergara R; Muñoz A; Toneatto D; Graña G; Wang H; Clemens R; Dull PM;
    Lancet; 2012 Feb; 379(9816):617-24. PubMed ID: 22260988
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A comparative evaluation of two investigational meningococcal ABCWY vaccine formulations: Results of a phase 2 randomized, controlled trial.
    Block SL; Szenborn L; Daly W; Jackowska T; D'Agostino D; Han L; Dull PM; Smolenov I
    Vaccine; 2015 May; 33(21):2500-10. PubMed ID: 25795256
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Temporal Changes in BEXSERO® Antigen Sequence Type Associated with Genetic Lineages of Neisseria meningitidis over a 15-Year Period in Western Australia.
    Mowlaboccus S; Perkins TT; Smith H; Sloots T; Tozer S; Prempeh LJ; Tay CY; Peters F; Speers D; Keil AD; Kahler CM
    PLoS One; 2016; 11(6):e0158315. PubMed ID: 27355628
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Characterization of invasive meningococcal disease case isolates in Atlantic Canada, 2014 to 2020: spatial-temporal variations of clones and predicted meningococcal B vaccine coverage.
    Tsang RSW; Law DKS; Zhou J; Haldane D; Garceau R; Zahariadis G; Mead K; Alexander D
    J Med Microbiol; 2022 Dec; 71(12):. PubMed ID: 36748536
    [No Abstract]   [Full Text] [Related]  

  • 55. Broad vaccine protection against Neisseria meningitidis using factor H binding protein.
    Findlow J; Bayliss CD; Beernink PT; Borrow R; Liberator P; Balmer P
    Vaccine; 2020 Nov; 38(49):7716-7727. PubMed ID: 32878710
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [From a pathogen's genome to an effective vaccine: the four-component meningococcal serogroup B vaccine].
    Abad R; Martinón-Torres F; Santolaya ME; Banzhoff A; González-Inchausti C; Graña MG; Vázquez JA
    Rev Esp Quimioter; 2019 Jun; 32(3):208-216. PubMed ID: 31148440
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Preclinical evidence for the potential of a bivalent fHBP vaccine to prevent Neisseria meningitidis Serogroup C Disease.
    Harris SL; Zhu D; Murphy E; McNeil LK; Wang X; Mayer LW; Harrison LH; Jansen KU; Anderson AS
    Hum Vaccin; 2011; 7 Suppl(Suppl):68-74. PubMed ID: 21245657
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Understanding immunogenicity assessments for meningococcal serogroup B vaccines.
    Balmer P; Beeslaar J; Findlow J; Srivastava A
    Postgrad Med; 2020 Mar; 132(2):184-191. PubMed ID: 32124678
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Meningococcal Antigen Typing System (MATS): A Tool to Estimate Global Coverage for 4CMenB, a Multicomponent Meningococcal B Vaccine.
    Boccadifuoco G; Brunelli B; Mori E; Agnusdei M; Gianfaldoni C; Giuliani MM
    Methods Mol Biol; 2019; 1969():205-215. PubMed ID: 30877679
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Product review on the IMD serogroup B vaccine Bexsero®.
    Deghmane AE; Taha MK
    Hum Vaccin Immunother; 2022 Dec; 18(1):2020043. PubMed ID: 35192786
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.